https://sciex.com/content/SCIEX/na/us/en


How fast is fast? The Echo® MS System sets the record

Sep 15, 2020 | Biopharma, Blogs, Echo MS, Pharma | 0 comments

How fast is fast?

Cheetahs. Usain Bolt. Tachyons. The Echo® MS system.

What do these things have in common?

They’re all fast. REALLY fast. In fact, they’re the fastest in their categories: the fastest land mammal, the fastest human sprinter, the fastest subatomic particle and the fastest high-throughput mass spectrometry sampling system.

The Echo® MS system sets a new speed record for quantitative mass spec analysis with the ability to analyze up to 3 samples per second. That’s up to 50 times faster than conventional LC-MS. 50 times! But the big difference here is that there is no LC.

That’s right. No LC.

Instead, the Echo® MS system uses Acoustic Droplet Ejection (ADE) to basically “vibrate” a nanoliter-sized droplet of sample directly out of the solution from a microwell plate into an Open Port Interface (OPI). Solvents within the OPI sweep the sample directly to the electrospray source of the MS system. Because of the dilution effects that occur within the OPI, matrix suppression effects are essentially eliminated, making for a very clean and sensitive analysis. As a result, most small molecules in drug discovery reach single-digit nanomolar-level sensitivity. And time-consuming sample preparation steps are no longer necessary.

Because there is no LC, contact areas required for conventional LC-MS, such as injection needles and loops, are removed. Sample introduction is achieved through a contactless interaction of the ADE with the OPI. Without these contact areas, carryover from sample to sample is virtually eliminated, even when moving between concentration extremes. Additionally, the lack of LC means the elimination of chromatographic run times as well as LC method development time.

In comparison to LC-MS

When compared to LC-MS, Chang Liu from SCIEX R&D sums it up nicely:

“The Echo® MS System is much faster, consumes much less sample, requires much less effort for sample preparation or method development and we could eliminate the carryover problems.”1

To increase throughput even more, the hardware and software of the Echo® MS System was designed for easy assimilation into high-throughput environments. Standard robot arms can easily transfer plates to and from the system.

With no sample preparation, no LC method development, no LC run time, incredibly fast sampling and high-throughput design considerations, the Echo® MS System is already changing the field of high-throughput analysis within drug discovery.

Don’t play by the rules. Change the game. And finish your work in record time. To learn more about this game-changing innovation and how you too can “Run Fast,” visit the Echo® MS System website for more information and see how fast is really fast.

References:

  1. Echo® MS System Product Announcement,  00:52:30

This blog is part 1 of a 3-part series on the Echo® MS System. Read part 2 (“Scale it up! The Echo® MS System delivers unprecedented levels of productivity”) and part 3 (“The Echo® MS System: Is it reproducible? Yes… yes… yes!”).

RUO-MKT-18-12281-A Echo® and Echo® MS are trademarks or registered trademarks of Labcyte Inc. in the United States and other countries, being used under license by SCIEX.

Is “right first time, every time” a pipedream for metabolite identification by LC-MS?

If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery.

Supporting new CRISPR gene editing systems

Prime editing (PE) is a next-generation gene editing technology that utilizes a Cas9 protein fused to a prime editing guide ribonucleic acid (pegRNA) to achieve high CRISPR/Cas9 editing efficiency and precision. However, the length requirement of pegRNAs at 120–250 nucleotides (nt) and their high level of secondary structure formation present analytical challenges for the purity analysis of chemically synthesized pegRNAs during development and quality control (QC).

A new approach for comprehensive AAV evaluation including full and empty analysis

Certain next-gen vaccines and gene therapy applications rely on the usage of adeno-associated viruses (AAV) as a delivery vehicle. To ensure the safety and efficacy of viral vector drugs, multiple critical quality attributes (CQAs) need to be well characterized.

Posted by

Neil Walsh is the Senior Manager for Pharma global strategic marketing at SCIEX. In this role, he manages both the strategic market and marketing for the pharmaceutical industry. Neil has spent all his working life entrenched in the pharmaceutical industry from active research, sales and business development through to strategic marketing. Outside of work Neil enjoys rugby, cycling and spending time with his family

Tags


0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial